Cardiac Arrhythmia Suppression Trial (CAST)

This study has been completed.
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI) Identifier:
First received: October 27, 1999
Last updated: June 23, 2005
Last verified: August 2004

To determine whether drug treatment of asymptomatic ventricular arrhythmias in post-myocardial infarction patients reduced the incidence of sudden cardiac death and total mortality.

Condition Intervention Phase
Cardiovascular Diseases
Coronary Disease
Death, Sudden, Cardiac
Heart Arrest
Heart Diseases
Myocardial Infarction
Myocardial Ischemia
Ventricular Arrhythmia
Drug: encainide
Drug: flecainide
Drug: moricizine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Prevention

Resource links provided by NLM:

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: August 1986
Estimated Study Completion Date: March 1998
  Show Detailed Description


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Men and women with ventricular premature depolarization six days to two years after the start of myocardial infarction.

  Contacts and Locations
Please refer to this study by its identifier: NCT00000526

Sponsors and Collaborators
Investigator: Alfred Hallstrom University of Washington
  More Information

Pratt CM, Ed: A Symposium: the Cardiac Arrhythmia Suppression Trial--Does it Alter Our Concepts of and Approaches to Ventricular Arrhythmias? Am J Cardiol, 65:1-42B, 1990. Identifier: NCT00000526     History of Changes
Other Study ID Numbers: 45
Study First Received: October 27, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Arrhythmias, Cardiac
Cardiovascular Diseases
Myocardial Ischemia
Coronary Artery Disease
Coronary Disease
Death, Sudden
Heart Arrest
Heart Diseases
Myocardial Infarction
Death, Sudden, Cardiac
Pathologic Processes
Vascular Diseases
Arterial Occlusive Diseases
Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action processed this record on February 14, 2013